Potential New Pharmacological Agents Derived From Medicinal Plants for the Treatment of Pancreatic Cancer

Azimi, Haniye; Khakshur, Ali Asghar; Abdollahi, Mohammad; Rahimi, Roja

doi:10.1097/mpa.0000000000000175

Cited by 24 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some in vitro studies have demonstrated synergistic effects in relation to reduction of the levels of proinflammatory cytokines (45,46), as well as synergistic antioxidant activities (47). Other investigations have also demonstrated that resveratrol and curcumin have synergistic anti-cancer activity (22,(49)(50)(51)(52)(53)64), as well as cardioprotective activity (54). In fact, with respect to carcinogenesis, Malhotra et al (53) conducted an in vivo study to verify the effects of curcumin and resveratrol in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats

Corrêa

Pires

Ribeiro

et al. 2016

J of Periodontal Research

130

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats

Corrêa

Pires

Ribeiro

et al. 2016

J of Periodontal Research

130

View full text Add to dashboard Cite

show abstract

“…It has been commonly used as a food additive or dietary pigment and in traditional medicine [ 12 , 13 , 14 , 15 , 16 ]. Preclinical in vitro and in vivo studies have demonstrated that curcumin has several pharmacologic effects, including antioxidant, anti-inflammatory, and anticancer activities, in different types of cancer, including PC, by modulating multiple signaling pathways [ 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ]. Taken together, these results suggest that curcumin can be considered a new therapeutic drug in PC treatment [ 45 ].…”

Section: Introductionmentioning

confidence: 99%

Curcumin AntiCancer Studies in Pancreatic Cancer

et al. 2016

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the deadliest cancers worldwide. Surgical resection remains the only curative therapeutic treatment for this disease, although only the minority of patients can be resected due to late diagnosis. Systemic gemcitabine-based chemotherapy plus nab-paclitaxel are used as the gold-standard therapy for patients with advanced PC; although this treatment is associated with a better overall survival compared to the old treatment, many side effects and poor results are still present. Therefore, new alternative therapies have been considered for treatment of advanced PC. Several preclinical studies have demonstrated that curcumin, a naturally occurring polyphenolic compound, has anticancer effects against different types of cancer, including PC, by modulating many molecular targets. Regarding PC, in vitro studies have shown potent cytotoxic effects of curcumin on different PC cell lines including MiaPaCa-2, Panc-1, AsPC-1, and BxPC-3. In addition, in vivo studies on PC models have shown that the anti-proliferative effects of curcumin are caused by the inhibition of oxidative stress and angiogenesis and are due to the induction of apoptosis. On the basis of these results, several researchers tested the anticancer effects of curcumin in clinical trials, trying to overcome the poor bioavailability of this agent by developing new bioavailable forms of curcumin. In this article, we review the results of pre-clinical and clinical studies on the effects of curcumin in the treatment of PC.

show abstract

“…Indeed, not surprisingly, diet and other chemical factors are increasingly being recognized for their importance in PDAC development and progression, even treatment [ 78 , 79 , 80 ]. Azimi et al [ 81 ] originally identified 12 natural compounds with beneficial effects against PDAC cells through four or more mechanisms. Several of these have been evaluated and found indeed to be inversely associated with PDAC risk [ 82 ].…”

Section: Dietary Considerationsmentioning

confidence: 99%

Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management

Jentzsch

Davis

Djamgoz

2020

Cancers

View full text Add to dashboard Cite

The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which comprises some 85% of all cases. Currently, this is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Commonly applied clinical therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest of the commonly occurring cancers. This review cultivates the hypothesis that the best management of PDAC would be possible by integrating ‘western’ clinical medicine with evidence-based complementary measures. Protecting the liver, where PDAC frequently first spreads, is also given some consideration. Overall, the complementary measures are divided into three groups: dietary factors, nutraceutical agents and lifestyle. In turn, dietary factors are considered as general conditioners, multi-factorial foodstuffs and specific compounds. The general conditioners are alkalinity, low-glycemic index and low-cholesterol. The multi-factorial foodstuffs comprise red meat, fish, fruit/vegetables, dairy, honey and coffee. The available evidence for the beneficial effects of the specific dietary and nutraceutical agents was considered at four levels (in order of prominence): clinical trials, meta-analyses, in vivo tests and in vitro studies. Thus, 9 specific agents were identified (6 dietary and 3 nutraceutical) as acceptable for integration with gemcitabine chemotherapy, the first-line treatment for pancreatic cancer. The specific dietary agents were the following: Vitamins A, C, D and E, genistein and curcumin. As nutraceutical compounds, propolis, triptolide and cannabidiol were accepted. The 9 complementary agents were sub-grouped into two with reference to the main ‘hallmarks of cancer’. Lifestyle factors covered obesity, diabetes, smoking, alcohol and exercise. An integrative treatment regimen was devised for the management of PDAC patients. This involved combining first-line gemcitabine chemotherapy with the two sub-groups of complementary agents alternately in weekly cycles. The review concludes that integrated management currently offers the best patient outcome. Opportunities to be investigated in the future include emerging modalities, precision medicine, the nerve input to tumors and, importantly, clinical trials.

show abstract

Potential New Pharmacological Agents Derived From Medicinal Plants for the Treatment of Pancreatic Cancer

Cited by 24 publications

References 0 publications

Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats

Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats

Curcumin AntiCancer Studies in Pancreatic Cancer

Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management

Contact Info

Product

Resources

About